BDBM388300 US10294230, Compound E1-1.4::US10584127, Compound E1-1.4::US11136328, Compound E1-1.4::US11752155, Compound E1-1.4B'

SMILES Fc1ccc(COC(=O)N2CC[C@H](CNc3nccn4cnnc34)C(F)(F)C2)cc1

InChI Key InChIKey=FXRLEHYPHSGRKY-UHFFFAOYSA-N

Data  1 KI  14 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 15 hits for monomerid = 388300   

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388300(US10294230, Compound E1-1.4 | US10584127, Compound...)
Affinity DataIC50: 20.5nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388300(US10294230, Compound E1-1.4 | US10584127, Compound...)
Affinity DataIC50: 1.00E+7nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388300(US10294230, Compound E1-1.4 | US10584127, Compound...)
Affinity DataIC50: 20.5nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388300(US10294230, Compound E1-1.4 | US10584127, Compound...)
Affinity DataIC50: 20.5nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388300(US10294230, Compound E1-1.4 | US10584127, Compound...)
Affinity DataIC50: 20.5nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388300(US10294230, Compound E1-1.4 | US10584127, Compound...)
Affinity DataIC50: 1.00E+7nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2020
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388300(US10294230, Compound E1-1.4 | US10584127, Compound...)
Affinity DataIC50: 20.5nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388300(US10294230, Compound E1-1.4 | US10584127, Compound...)
Affinity DataIC50: 1.00E+4nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388300(US10294230, Compound E1-1.4 | US10584127, Compound...)
Affinity DataIC50: 20.5nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388300(US10294230, Compound E1-1.4 | US10584127, Compound...)
Affinity DataIC50: 20.5nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388300(US10294230, Compound E1-1.4 | US10584127, Compound...)
Affinity DataIC50: 20.5nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388300(US10294230, Compound E1-1.4 | US10584127, Compound...)
Affinity DataIC50: 20.5nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388300(US10294230, Compound E1-1.4 | US10584127, Compound...)
Affinity DataIC50: 1.00E+7nMAssay Description:This example describes an NR2B receptor binding assay in rat brain using [3H] (E)-N1-(2-methoxybenzyl)-cinnamidine (see below). The binding assay met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388300(US10294230, Compound E1-1.4 | US10584127, Compound...)
Affinity DataIC50: 20.5nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388300(US10294230, Compound E1-1.4 | US10584127, Compound...)
Affinity DataKi:  18.2nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent